Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (79)	8/27/1997 1:39:00 AM
From: SteveG	of 496

<According to this press release and what is available in literature and in patents, it appears that they do not exhibit immunosuppressive effects:> Yes, ostensibly, very clearly stated in the press release (which is from last Neuroscience). You now have me intrigued, Miljenko. Thank you for pointing this out. I also find it odd that this was not questioned at the conference call. Would you be interested in querying Guilford/Amgen on this? From a previous press release, Angela Webber (of Guilford) is at 410-631-6449 and Jeanne Flynn (of Amgen) is at 805-447-3390. I suggest this to you, as you have brought up these critical points - which all analysts seemed to have missed (or avoided?). I encourage you to do so, as you seem familiar with both classes of these neurotrophic compounds, especially those of Vertex. And thank you for your perspective on Guilford's vs. Vertex's R&D strengths and weaknesses. Steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next